Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration

Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration to Evaluate Its Safety in Patients With Acute Myocardial Infarction

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07400458

Enrollment

100

Registered

2026-02-10

Start date

2022-03-03

Completion date

2032-09-30

Last updated

2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Brief summary

This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.

Detailed description

To evaluate the safety for 60 months after a single dose of Hearticellgram-AMI in patients with Acute Myocardial Infarction.

Interventions

BIOLOGICALHearticellgram-AMI

Patients who had administered Hearticellgram-AMI.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Those who had administered Hearticellgram-AMI 2. Those who voluntarily agreed in writing to participate in this investigation

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Rate of AESI	For 5 years	death, neoplasms or malignancies in tissues or organs, Immune response

Countries

South Korea

Contacts

CONTACTDAEUN JUNG

daeun4100@pharmicell.com82-2-3496-0134

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026